Drug Profile
Leuprorelin implant - Ardana Bioscience
Latest Information Update: 18 Nov 2021
Price :
$50
*
At a glance
- Originator Ardana Bioscience
- Developer Ardana plc
- Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
- Mechanism of Action Gonadotropin releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 25 Aug 2004 Leuprorelin implant is available for licensing (http://www.ardana.co.uk)
- 01 Jun 2004 AEterna Laboratories changed its name to AEterna Zentaris
- 19 Aug 2003 Phase-II clinical trials in Prostate cancer in United Kingdom (SC)